Bausch Health Companies Inc. (BHC): what the price assumes

In the published model solve dated 2026-Q2, anchored at $6.56, Bausch Health Companies Inc. (BHC) is priced for +10.5% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/BHC

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 4.2% sits below it).

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 2.2%); the inversion above states its own rate.

Per-Model Detail (n=2)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Equity here is a thin residual: about 1.7 billion dollars of market value sits above roughly 19.5 billion of net borrowings, so a small move in the value of the whole enterprise swamps the share price in either direction.
• The growth is coming from the asset with the shortest legal clock, with Salix segment profit up 26% to $468 million in the March 2026 quarter and the 10-Q stating that "Xifaxan was the primary contributor to growth for the three months ended March 31, 2026".
• Second-quarter results arrive after the close on July 29, 2026, and the long-discussed separation of Bausch + Lomb remains tied to hitting targeted leverage rather than to a date.

Bull Case

Start at the bottom of the capital structure and work upward, because that is where this equity actually sits. Bausch Health is a mature collection of prescription, consumer and eye-care franchises, not a growth story, and the ordinary tools for reading a mature company do not fit it. Trailing net income is negative by about 1.2 billion dollars, so there is no earnings multiple to work with. What there is instead is an enterprise worth roughly 21.4 billion dollars, of which the shareholders own the last slice. That geometry is the bull case in a sentence: an enterprise moving 10% is worth more than the entire equity market value today.

And the operations are moving in the right direction. Revenues in the March 2026 quarter came in at "$2,524 million and $2,259 million for the three months ended March 31, 2026" and the year-ago period, growth of about 12%. That is a level of top-line movement that a business at this stage is not supposed to produce, and it is broad rather than concentrated in a single line.

Salix is doing most of the heavy lifting. Its segment profit "for the three months ended March 31, 2026 and 2025 was $468 million and $371 million, respectively, an increase of $97 million, or 26%", and the filing attributes that to higher revenue plus lower selling and administrative expense. Twenty-six percent profit growth in a segment of this size is not a rounding effect. It is the operating leverage a specialty pharmaceutical franchise produces when volume rises against a fixed sales force.

The eye-care business is compounding more quietly. Bausch + Lomb segment revenue was "$1,244 million and $1,137 million for the three months ended March 31, 2026 and 2025, respectively, an increase of $107 million, or 9%", with 42 million of that increase coming from currency. Bausch Health holds roughly 87% of Bausch + Lomb's outstanding shares, and management continues to say the separation makes strategic sense once leverage targets are met. A separately listed asset that keeps growing at high single digits is a live source of proceeds that most levered pharmaceutical companies do not have.

The bull has to concede the obvious: interest expense is enormous relative to what the business currently earns, and the refinancing schedule is a permanent chore. But the company has been doing exactly that chore. The 10-K describes the April 2025 refinancing accounted for as an extinguishment of debt and a December 2025 exchange in which "126NumberCo issued $ 1,600 million of such incremental equivalent debt in the form of new 2032 Senior Secured Notes". Pushing maturities out is not deleveraging. It is buying the operating recovery time to work, and time is precisely what a residual claim needs.

Bear Case

The product doing the most work right now is also the one with a clock on it. Salix grew 26% in the March quarter on Xifaxan, and the 10-K is explicit about what surrounds that product: "for a number of our products (including Xifaxan ® 550 mg, Trulance ® , Cabtreo ® and Lumify ® in the U.S), we have commenced (or anticipate commencing) and have (or may have) ongoing infringement proceedings against potential generic competitors in the U.S. If we are not successful in these proceedings, we may face increased generic competition". The company also warns that following a loss of exclusivity "we would anticipate that product sales for such product would decrease significantly shortly" afterward, and that for products already past exclusivity "we anticipate that generic competitors may launch in 2026 or in later years". This is a moat with a published expiry, defended in court.

One of the litigants on the other side is a company whose numbers sit in plain view. AMRX, named in the Xifaxan proceedings alongside Norwich Pharmaceuticals, runs a 14.3% operating margin on $3.05B of revenue growing 7.6%, and it holds 61 products with pending applications and another 43 in development. A challenger with that cost base does not need to win quickly. It needs to win once. Meanwhile the concentration is going the wrong way: every quarter Salix outgrows the rest of the company, more of the equity value depends on the outcome of a patent docket.

Then there is the arithmetic that governs everything else. The 10-K reports that "Interest expense was $1,604 million and $1,388 million" for 2025 and 2024, an increase of "$216 million, or 16%". Trailing operating profit is about $389 million. Read those two figures together and the picture is unambiguous: the business currently earns about a fifth of its own interest bill from operations, and net borrowings sit near 50 times operating profit. Every dollar of operating improvement is spoken for before it reaches a shareholder. That, not the multiple, is what the equity is actually underwriting.

The escape hatch is narrower than it looks. Monetising Bausch + Lomb is the obvious way to fix the balance sheet, but the credit agreements have already claimed those proceeds: the 2030 term loan carries "a 100 % net cash proceeds sweep, on a pro rata basis with obligations under the 2032 Senior Secured Notes, in connection with (i) the receipt of net cash proceeds from the sale or disposition of Bausch + Lomb Share Collateral". A sale delivers cash to lenders first, and the separation itself is conditioned on reaching leverage targets, which is a circular requirement: the transaction that would reduce leverage waits on leverage being reduced.

The price, for its part, is not priced for stagnation. At the enterprise level it works out to roughly 40 times trailing operating profit, which under a single set of fixed assumptions implies operating profit compounding around 18% a year for five years. Treat that as a direction rather than a measurement. The direction is enough: it says the market is already crediting a sustained operating recovery at a company where a court, not management, controls the largest single input to it. A fair bear grants that the March quarter was genuinely good and that Bausch + Lomb has real independent value. The counter is that at this level of leverage, being right about the business and wrong about the timing produces the same outcome for the equity as being wrong about both.

Valuation

At $4.44 the shares are less a claim on a business than a claim on what remains after the lenders. Market value is about 1.7 billion dollars. The enterprise it sits on top of is worth roughly 21.4 billion, with net borrowings near 19.5 billion filling the gap. More than nine-tenths of the capital financing these franchises belongs to somebody else, and that single fact governs how every other number in the report should be read.

It also explains why the usual valuation approaches have so little purchase. Trailing net income is negative by about 1.2 billion dollars, so there is no profit figure to apply a multiple to, and price-to-sales comparisons across a company that spans prescription dermatology, gastrointestinal therapies, contact lenses and consumer eye drops compare portfolios that share almost nothing. What is left is the enterprise arithmetic, and there the price is not conservative. Roughly 40 times trailing operating profit at the enterprise level implies, under one set of fixed discount and fade assumptions, operating profit compounding near 18% a year for five years. Keep that approximate; the point is its direction, which is that a recovery is already in the price rather than waiting to be discovered.

The operating base underneath is real but thin. Revenue runs about $10.53B with a trailing operating margin near 3.9%. Set that beside the cohort. AMRX earns a 14.3% operating margin on $3.05B of revenue, growing 7.6%. OGN turns $6.16B of revenue into a 4.0% profit margin with sales down 2.1%. VTRS, at $14.56B of revenue, converts under one percent of it to operating profit. Bausch Health sits at the low end of that distribution on margin while carrying the highest leverage in it, which is the combination that makes the equity behave like an option rather than a share.

Solvency is therefore not a footnote here; it is the analysis. Interest expense was "$1,604 million" in 2025 against about $389 million of trailing operating profit, leaving coverage near 0.2. Net borrowings run about 50 times operating profit. The share count has been close to steady, rising about 0.8% a year over four years, so dilution is not the pressure; the pressure is the coupon. Two things would change that picture: a large operating step-up, which the March quarter's 12% revenue growth and 26% Salix profit growth argue is at least underway, or a Bausch + Lomb monetisation, whose proceeds the credit agreements have already routed to lenders. Both are visible. Neither is quick.

Catalysts

Two clocks are running here, and only one has a date on it. Bausch Health reports second-quarter 2026 results after the close on Wednesday, July 29, 2026, with a call at 5:00 p.m. Eastern. The number that matters is not revenue, which has been growing, but the gap between segment profit and the interest line. The March quarter closed that gap; whether it kept closing is what the print answers.

The second clock is legal and has no fixed date. The 10-K discloses ongoing Paragraph IV proceedings concerning Xifaxan 550 mg tablets against Norwich Pharmaceuticals and Amneal, and separately notes that for products that already lost exclusivity "we anticipate that generic competitors may launch in 2026 or in later years". Any docket movement on rifaximin is a larger event for this equity than a quarterly beat, because Salix profit growth is currently the main thing supporting the enterprise value the shares sit on top of.

The third item is structural. As of April 22, 2026 the company indirectly held 310,449,643 common shares of Bausch + Lomb, roughly 87% of that company, and continues to describe a separation, whether by monetisation, distribution to shareholders, or a combination, as strategically sensible subject to reaching targeted leverage ratios and obtaining approvals. There is no announced timetable. Progress toward those leverage targets, disclosed quarter by quarter, is the closest thing to a countdown available.

Peer Cohorts (Per Segment, With Filing Citations)

Salix (reported)

• OGN (Organon & Co.)
• FY2025 10-K: …injuries, all of which have been tolled under a written tolling agreement. There is one matter involving Nexplanon pending in state court in California. As of December 31, 2025, Merck had 17 cases pending outside the United States, of which seven relate to Implanon and eleven relate to Nexplanon . Securities and…
• FY2025 10-K: …in the United States in in the name of Immunex Corporation; Remicade is a trademark registered in the United States in in the name of Janssen Biotech, Inc.; Avastin, Perjeta and Herceptin are trademarks registered in the United States in in the name of Genentech, Inc.; Clarinex is a trademark registered in the United…
• TEVA (TEVA PHARMACEUTICAL INDUSTRIES LIMITED)
• FY2025 10-K: …acquired. The increase in 2025 resulted mainly from higher cash flow generated from operating activities. Dividends We have not paid dividends on our ordinary shares or ADSs since December 2017. Commitments In addition to financing obligations under short-term debt and long-term senior notes and loans, debentures and…
• FY2025 10-K: …by or made from living cells or organisms. Biosimilars are highly similar to the reference biologic, in both structure and function (e.g., pharmacodynamics, pharmacokinetics, safety, efficacy and immunogenicity) and, for any approved uses, have no clinically meaningful differences from the reference product in terms…
• AMRX (AMNEAL PHARMACEUTICALS, INC.)
• FY2025 10-K: …Puerto Rico. We retain regulatory responsibility and continue to supply ALYMSYS ® under our agreement with mAbxience S.L. The arrangement includes a tiered profit‑sharing structure and has an initial term through 2028. Refer to Note 4. Alliance and Collaboration . In March 2024, we amended the Kashiv Biosimilar…
• FY2025 10-K: …amrx:ResearchAndDevelopmentReimbursementMember 2020-08-01 2020-08-31 0001723128 srt:AffiliatedEntityMember amrx:KashivBioSciencesLLCMember amrx:GanirelixAcetateAndCetrorelixAcetateMember amrx:DevelopmentMilestonesMember amrx:ResearchAndDevelopmentReimbursementMember 2020-08-01 2020-08-31 0001723128…
• PBH (PRESTIGE CONSUMER HEALTHCARE INC.)
• FY2025 10-K: …Position (1) Market Segment (2) Brand Information North American OTC Healthcare: (3) BC and Goody's Analgesics #1 Analgesic Powders Founded over 90 years ago, the BC and Goody's brands feature over-the-counter, fast-acting pain relief powder Boudreaux's Butt Paste Dermatologicals #3 Baby Ointments Products include…
• FY2025 10-K: …#1 Vaginal Anti-Fungal Provides fast relief for yeast infections and is available in several different doses Nix Dermatologicals #1 Lice and Parasite Treatments Effective and safe lice and super lice treatments Summer's Eve Women's Health #1 Feminine Hygiene Offers a variety of feminine care products including…
• SUPN (SUPERNUS PHARMACEUTICALS, INC.)
• FY2025 10-K: …in the U.S. and certain other foreign countries. These patents are owned by Sage Therapeutics, LLC, and are licensed to Supernus Pharmaceuticals, Inc. SPN-817 (huperzine A) We have two patents issued in the U.S., and in China, Mexico, and certain other foreign countries relating to extended-release formulations of…
• FY2025 10-K: Exchange Commission. Accordingly, disruptions to the Company's business as a result of a pandemic could result in a material adverse effect on the Company's business, results of operations, financial condition, and prospects in the near and long terms. There can be no assurance that any of the Company's plans will be…
• COR (CENCORA, INC.)
• FY2025 10-K: …divestitures. • New Reporting Structure. Recently, we undertook a strategic review of our business to ensure alignment with our growth priorities and strategic drivers. As a result of this review, we have reorganized certain business components within our reporting structure. Beginning in the first quarter of fiscal…
• FY2025 10-K: …for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Factors that may be considered a change in circumstances indicating that the carrying value of our long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, or…

Solta Medical (reported)

• OGN (Organon & Co.)
• FY2025 10-K: Solutions Ltd., the product developer for Tofidence . In the first quarter of 2025, the Company recognized an intangible asset of $ 51 million, related to the upfront payment to Biogen, which will be amortized over 10 years. Shanghai Henlius Biotech, Inc. ("Henlius") In November 2025, the FDA approved the Biologics…
• FY2025 10-K: …include the following products, which are primarily used for medically-assisted reproduction ("MAR") and/or in vitro fertilization ("IVF") treatment cycles: Follistim AQ, which is marketed as Puregon in most countries outside the United States, contains human follicle-stimulating hormone ("FSH") and is used to…
• TEVA (TEVA PHARMACEUTICAL INDUSTRIES LIMITED)
• FY2025 10-K: …for MS treatments continues to develop, particularly with the approval of alternative therapies and generic versions of COPAXONE. Oral branded and generic treatments for MS, continue to present significant and increasing competition. COPAXONE also continues to face competition from existing injectable products, as…
• FY2025 10-K: …our three business segments: United States Segment We are one of the leading generic pharmaceutical companies in the United States. We market more than 350 generic prescription products in more than 1,100 dosage strengths, packaging sizes and forms, including oral solid dosage forms, injectable products, inhaled…
• AMRX (AMNEAL PHARMACEUTICALS, INC.)
• FY2025 10-K: …As of December 31, 2025, our Affordable Medicines segment had 61 products with a pending ANDA and another 43 products in various stages of development in our pipeline, 95% of which are non-oral solid products. We have an integrated, team-based approach to product development that combines our formulation, regulatory,…
• FY2025 10-K: …from carbon monoxide or manganese poisoning in adults. RYTARY ® is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. UNITHROID ® , indicated for the treatment of hypothyroidism, is sold under a…
• VTRS (Viatris Inc)
• FY2025 10-K: …rebates for certain Medicare drugs. The implementation of the Inflation Reduction Act, including the drug price negotiation provision, inflation penalties, and Part D redesign is currently underway and could negatively affect certain Viatris portfolio products based on future pricing decisions, changes in the…
• FY2025 10-K: …chronic night driving impairment in keratorefractive patients with reduced mesopic vision. ▪ Announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) in treating presbyopia, the age-related progressive loss of the ability to focus on…
• PRGO (Perrigo Company plc)
• FY2025 10-K: …including the Physiomer ® brand; • Pain & Sleep-Aids: Net sales of $235.4 million increased 6.0%, inclusive of a 4.0% favorable effect of currency translation, due primarily to restored supply of the Solpadeine ® brand; • Healthy Lifestyle: Net sales of $231.5 million increased 2.5%, inclusive of a 0.6% favorable…
• FY2025 10-K: …primarily in Europe and Australia. During the first quarter of 2026, we have begun transitioning from a geographic segment reporting structure to a category-based segment view, enabling us to better align our financial disclosures and operational analysis with our product offerings and strategic priorities. The…
• JAZZ (Jazz Pharmaceuticals plc)
• FY2025 10-K: Health Options, Inc., collectively FSS Federal Supply Schedule pricing program FTC Federal Trade Commission GDPR EU's General Data Protection Regulation GEA gastroesophageal adenocarcinoma GHB gamma-hydroxybutyric acid GMP Good Manufacturing Practice Granules Granules India Limited GW GW Pharmaceuticals plc GW…
• FY2025 10-K: …therapy. • Zepzelca® (lurbinectedin) , a product approved by FDA in June 2020 under FDA's accelerated approval pathway and launched in the U.S. in July 2020 for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy; approved by FDA in October 2025 in…
• ANIP (ANI PHARMACEUTICALS, INC)
• FY2025 10-K: …("ANDAs"), New Drug Applications ("NDAs"), product rights, and entry into agreements to obtain the distribution rights for various products. We expect that our robust pipeline will continue to yield approximately 10 to 15 new product launches per year. We expect to continue to expand our Rare Disease and Brands…
• FY2025 10-K: …chronic autoimmune disorders, including acute exacerbations of multiple sclerosis ("MS") and rheumatoid arthritis ("RA"), in addition to excess urinary protein due to nephrotic syndrome. Cortrophin Gel is an adrenocorticotropic hormone ("ACTH"), also known as purified corticotropin. On January 24, 2022, we announced…
• ABBV (AbbVie Inc.)
• FY2025 10-K: …associated with a neurologic condition in adults who have an inadequate response to an anticholinergic medication. In addition, Botox Therapeutic is approved to treat spasticity in patients two years of age and older, cervical dystonia in adults as well as other conditions. Botox is marketed in other countries around…
• FY2025 10-K: …The company also made a decision to reduce current sales and marketing investment related to Durysta, an on-market eye care product to treat elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Each of these strategic decisions contributed to decreases in the estimated future cash flows for…

Diversified (reported)

• TEVA (TEVA PHARMACEUTICAL INDUSTRIES LIMITED)
• FY2025 10-K: …We are committed to integrating, where appropriate, artificial intelligence ("AI") technologies in our operations, in an effort to deliver innovative solutions to our customers, patients and stakeholders. Our initiatives include leveraging machine learning and generative AI to optimize internal processes and…
• FY2025 10-K: Our Business Segments We operate our business through three segments: United States, Europe and International Markets. Each business segment manages our entire product portfolio in its region, including generics, which includes biosimilars and OTC products, as well as innovative medicines. This structure enables…
• AMRX (AMNEAL PHARMACEUTICALS, INC.)
• FY2025 10-K: …As of December 31, 2025, our Affordable Medicines segment had 61 products with a pending ANDA and another 43 products in various stages of development in our pipeline, 95% of which are non-oral solid products. We have an integrated, team-based approach to product development that combines our formulation, regulatory,…
• FY2025 10-K: …ceases to be a highly effective hedge, the Company discontinues hedge accounting and any deferred gains or losses related to a discontinued cash flow hedge shall continue to be reported in accumulated other comprehensive (loss) income net of income taxes, unless it is probable that the forecasted transaction will not…
• OGN (Organon & Co.)
• FY2025 10-K: …considered in the assessment include regulatory and status of clinical testing, commercial and competitive landscape, legal and financial considerations for the indefinite-lived intangibles. If we conclude it is more likely than not that the fair value is less than its carrying amount, a quantitative impairment test…
• FY2025 10-K: …intangible assets related to IPR&D are also determined using an income approach, through which fair value is estimated based on each asset's probability-adjusted future net cash flows, which reflect the different stages of development of each product and the associated probability of successful completion. The net…
• PRGO (Perrigo Company plc)
• FY2025 10-K: …factors give us a competitive advantage and provide value to our customers and consumers: • A diverse product portfolio, leadership in first-to-market product development, and product life cycle management; • Experienced research and development ("R&D"), innovation and regulatory capabilities to develop and launch…
• FY2025 10-K: …and consumer product companies, such as Haleon, Kenvue, Procter & Gamble, Reckitt Benckiser, Abbott Nutrition, Bayer AG, Opella, Philips, Teva, Viatris, and Stada. Each product category of our business has certain key competitors, such that a competitor generally does not compete across all product lines or across…
• ANIP (ANI PHARMACEUTICALS, INC)
• FY2025 10-K: …and a sales force for these products. Strengthening Our Generics and Other Segment We plan to strengthen our Generics and Other segment through continued investment in our research and development capabilities and increased focus on niche opportunities. We have grown our Generics business through a combination of…
• FY2025 10-K: …chain and inventory expectations, and our and our partners' ability to meet anticipated demand; • selling and marketing strategies and associated costs to support the sales of our branded products, including Purified Cortrophin® Gel (Repository Corticotropin Injection USP) ("Cortrophin Gel") and ILUVIEN® ("ILUVIEN");…
• VTRS (Viatris Inc)
• FY2025 10-K: EventMember 2026-01-01 2026-03-31 0001792044 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember vtrs:BioconBiologicsMember 2023-01-01 2023-12-31 0001792044 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember vtrs:BioconBiologicsMember 2025-01-01 2025-12-31 0001792044…
• FY2025 10-K: …derivative instrument qualifies as a cash flow hedge or a net investment hedge, changes in the fair value are deferred through other comprehensive earnings. If a derivative instrument qualifies as a fair value hedge, the changes in the fair value, as well as the offsetting changes in the fair value of the hedged…

Bausch + Lomb (reported)

• ALC (Alcon Inc.)
• FY2025 20-F: …Innovation drives every aspect of our business as we strive to deliver new, best-in-class products for customers and patients. From early-stage discovery to clinical deployment, our global research and development (R&D) capabilities span clinical research, optical design, material and surface chemistry, software…
• FY2025 20-F: …and companies that promote alternative approaches for responding to the conditions our products address. At any time, our known competitors and other potential market entrants may develop new devices or treatment alternatives that may compete directly with our products. In addition, they may gain a market advantage…
• COO (The Cooper Companies, Inc.)
• FY2025 10-K: …and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation. • Limitations on sales following product introductions due to poor market acceptance. 5 THE COOPER COMPANIES, INC. AND SUBSIDIARIES • New competitors,…
• FY2025 10-K: …progress. Through our Connection & Belonging (C&B) strategy, we drive a culture where individual qualities and backgrounds are highly valued and respected, and our employees feel a sense of belonging. Our C&B strategy includes initiatives to promote C&B conversations and training to inform and educate our workforce,…
• GKOS (GLAUKOS Corp)
• FY2025 10-K: …of corneal crosslinking therapies such as PeschkeTrade GmBH. Our anterior segment pipeline, if approved, would vastly expand our competition to numerous large companies such as AbbVie Inc., Alcon, Inc. and Johnson & Johnson, as well as some small companies that provide medical technology and pharmaceutical therapies…
• FY2025 10-K: …supporting the above personnel growth as well as our ongoing administrative operations, inclusive of information technology, facilities and allocated expenses; as well as reserves for accounts receivable, which are calculated based on our accounts receivable reserve methodology. Research and Development Expenses R&D…
• STE (STERIS plc)
• FY2025 10-K: …12. COMMITMENTS AND CONTINGENCIES We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers,…
• FY2025 10-K: …maintain, upgrade, repair, and troubleshoot capital equipment throughout the world. We offer various preventive maintenance programs and repair services to support the effective operation of capital equipment over its lifetime. Our Healthcare segment also provides comprehensive instrument, devices, and endoscope…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.